68 Ga-FAPI04 Versus 68 Ga-DOTATATE PET/CT in a Patient With Multiple Meningioma.

Denizmen D., Isik E. G., Buyukkaya F., Kuyumcu S.

Clinical nuclear medicine, vol.48, no.5, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 5
  • Publication Date: 2023
  • Doi Number: 10.1097/rlu.0000000000004617
  • Journal Name: Clinical nuclear medicine
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
  • Keywords: 68Ga-DOTATATE, 68Ga-FAPI04, atypical meningioma, cancer-Associated fibroblast, FAPI, fibroblast activation protein inhibitor
  • Istanbul University Affiliated: Yes

Abstract

We present the 68Ga-DOTATATE and 68Ga-FAPI (fibroblast activation protein inhibitor) PET/CT findings of a 61-year-old man diagnosed with atypical World Health Organization grade II multiple meningiomas. The patient has been stable for 2 years following multiple surgeries and external radiotherapy because of recurring disease until he recently described frequent headaches, and a follow-up examination confirmed new meningioma lesions on MRI. However, the patient was inoperable and was referred for 68Ga-DOTATATE PET/CT to determine eligibility for salvage peptide receptor radionuclide therapy. He also underwent fibroblast activation protein-Targeted imaging using 68Ga-FAPI04 PET/CT, which revealed heterogeneous, low to mild fibroblast activation protein expression across multiple meningioma lesions.